65
Participants
Start Date
October 29, 2015
Primary Completion Date
June 2, 2017
Study Completion Date
June 2, 2017
empagliflozin 10mg
empagliflozin 25 mg
Placebo
For blinding purposes
Kunisaki Makoto Clinic, Fukuoka, Fukuoka
Seino I.M. Clinic, Fukushima, I.M., Fukushima, Koriyama
Nippon Kokan Fukuyama Hospital, Hiroshima, Fukuyama
Nakakinen Clinic, Ibaraki, Naka
Kubota Clinic, Kanagawa, Kawasaki
Medical Corporation Yuga Higashirinkan Kaneshiro Diabetes Clinic, Kanagawa, Yamato-shi
Yokohama Minoru Clinic, Kanagawa, Yokohama
Yokkaichi Diabetes Clinic, Mie, Yokkaichi
Shiraiwa Medical Clinic, Osaka, Kashiwara-shi
AMC Nishi-umeda Clinic, Osaka, Osaka-shi
OCROM Clinic, Osaka, Suita
Fukuwa Clinic, Tokyo, Chuo-ku
Tokyo-Eki Center-building Clinic, Tokyo, Chuo-ku
Minamino Heart Clinic, Tokyo, Hachioji
ToCROM Clinic, Tokyo, Shinjuku-ku
Shinjuku Research Park Clinic, Tokyo, Shinjuku-ku
Lead Sponsor
Boehringer Ingelheim
INDUSTRY